Metered Dose Inhalers 101


Moderated by: Peter Mack (AstraZeneca/Pearl Therapeutics)

About the Webinar: Inhalation products are designed to deliver drug into the lung locally to treat respiratory disease or systemically to treat non-respiratory disease. The devices used to deliver inhaled medicines include nebulizers, metered dose inhalers (MDIs), dry power inhalers (DPIs), and more recently soft mist inhalers. Each drug delivery device has its own formulation requirements, strategies, challenges, and opportunities that need to be considered when developing new inhalation products. Moreover, due to these combined formulation and device considerations, inhalation product development requires multidisciplinary technical knowledge and experience to solve complex problems and deliver robust products to patients who need them.

The intent of this webinar is to introduce formulation scientists, device engineers, and other pharmaceutical professionals to the core technical considerations of respiratory drug delivery. This webinar will focus on metered dose inhaler (MDI) development, specifically basics of formulation science for MDI solutions and suspensions, device design for MDI componentry (valve, can, and actuator), and how these factors combine to influence the inhalation product performance. Insights will also be provided on recent advances in MDI formulation and device technologies and the need these new technologies are meeting.

Learning Objectives:

  • Understand and review a broad technical foundation on the basics of metered dose inhaler science.
  • Gain insight into historical perspective on metered dose inhalers as well as emerging technologies.


  • Mark Sommerville, Ph.D. (AstraZeneca/Pearl Therapeutics)

    Mark obtained his BS in biochemistry from Virginia Tech, and a masters degree in pharmacology from Case Western Reserve. After working as an analytical organic chemist and bioanalytical chemist for 10 years, he found his niche in pharmaceutical formulation. After a doctorate at UNC Chapel Hill with Tony Hickey, he worked at GlaxoSmithKline for 8 years in MDI formulation, making contributions in the areas of MDI science, foreign particulate analysis, extractables and leachables characterization, spray drying, and novel excipients.

    After GSK Mark joined Pearl Therapeutics in 2008, where he has worked in various areas including analytical method development, valve conditioning procedures, valve design, formulation development, extractables and leachables, CT analysis, electrostatics, and foreign particulate matter evaluation. He is the SEM lead and consults across departments on a variety of topics.

January 18, 2018
Thu 12:30 PM EST

Duration 1H 30M

Register Already Registered? System Requirements »